4 Things You Should Know About the Paleo Diet
It is well known that cutting out refined foods, sugar, and added salt will benefit your health. But the benefits of the other aspects of the Paleo Diet, …
Go to Source
Month: April 2015
Sam Smith Paleo Diet Weight Loss: Goal Weight Only 4 Pounds Away After Losing 14 Pounds In …
Sam, 22, said the diet principles in “Eat Nourish Glow” helped him lose weight rapidly and dramatically improved his health, Examiner reported.
Go to Source
Sam Smith Looks Better Than Ever After Astonishing Weight Loss
Celebuzz reports about how “Eat, Nourish, Glow is a book by author Amelia Freer, a nutritional therapist and healthy diet expert. The publication …
Go to Source
Essential Health
The Mayo Clinic also stated that nearly 40 percent of adults reported using complementary and alternative medicine. Essential oils, which is a highly …
Go to Source
A timely study on alternative medicine
Conventional medicine has been slow to wholly embrace an alternative protocol in the field of wellness. For good reason, some might argue. Despite …
Go to Source
Blood Tests Could be the New Alternative to Biopsies for Cancer Detection
With new scientific and medical advancements coming up everyday, and newer, non-invasive diagnostic techniques being introduced, there is a lot of …
Go to Source
Merck’s Keytruda shrinks lung cancer tumors, FDA approval sought
Merck & Co Inc’s Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body’s own disease-fighting cells. The company said it has filed for U.S. Food and Drug Administration approval of the drug as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease has worsened despite previous treatment. Keytruda, also known as pembrolizumab, belongs to a new class of drugs designed to help the immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1. Merck said its FDA lung cancer filing is for patients with both squamous and non-squamous NSCLC.
Go to Source
7 top tips for losing weight, according to Derbyshire-based Slimming World consultant
Slimming World's eating plans are suitable for the whole family. … To ensure a healthy balanced diet, the plan also includes daily measured portions …
Go to Source
Excitement, vigour mark launch of AAP government's public budgeting exercise
NEW DELHI: The excitement was palpable at the tiny, largely lower middle class locality of east Delhi where the AAP government's unique …
Go to Source
Clinton supporter: Benghazi probe a 'political exercise'
Sen. Claire McCaskill (D-Mo.) on Sunday said the congressional investigation into the deadly attack on the U.S. diplomatic compound in Benghazi, …
Go to Source
Arvind Kejriwal-led AAP govt kicks off 'participatory budget' exercise
The Aam Aadmi Party-led (AAP) Delhi government today kicked off its first “participatory budget” exercise amidst much fanfare and enthusiasm at a …
Go to Source
Teva shares slide on generic Copaxone fears
By Steven Scheer and Tova Cohen TEL AVIV (Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva's Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news hit the market on Thursday after Israel's market closed for the weekend. Teva's New York-listed shares fell 3.8 percent on Thursday but gained 2.2 percent on Friday, ending the week at $64.91. In a potentially major blow for Teva, the U.S. Food and Drug Administration approved the first generic version of multiple sclerosis drug Copaxone, which accounts for about half the company's profit.